Compare GSK plc (GSK) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: GSK plc is far larger — about 252.4× YieldMax Universe Fund of Option Income ETFs's market cap, and GSK plc pays a 3.9% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| GSK | YMAX | |
|---|---|---|
Market Cap | $91.88B | $364M |
Volume | 7,730,529 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $12.98 |
52-Week Low | $43.24 | $7.27 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
YMAX trades at $7.61, up 1.06% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF maintains a high distribution yield, paying weekly dividends, though recent news highlights concerns about net asset value erosion. Key support is at $7, with resistance at $8.
The outlook is cautious due to structural risks from the fund-of-funds fee structure and declining share price despite distributions. Opportunities exist for income-focused investors seeking high yield, but principal erosion remains a significant risk. Analyst sentiment is neutral to bearish, emphasizing sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
